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RARE SYNDROMES: WHAT THEY TEACH US ABOUT OSTEOARTHRITIS
DISEASE MECHANISMS
J.A. Gallagher. Univ. of Liverpool, Liverpool, United Kingdom
William Harvey, the great English physician of the 17th century
observed “Nature is nowhere accustomed more openly to display her
secret mysteries than in cases where she shows tracings of her work-
ings apart from the beaten paths; nor is there any better way to
advance the proper practice of medicine than to give our minds to the
discovery of the usual law of nature, by careful investigation of cases of
rarer forms of disease”. Harvey’s words have indeed been prophetic;
the biomedical literature contains numerous examples of how research
on the extreme phenotypes of monogenic diseases has helped eluci-
date the molecular pathogenesis of more common disorders. Several
therapies for common diseases, including the blockbuster drugs statins
and bisphosphonates, were discovered in part through the study of rare
syndromes.
Despite the examples from other ﬁelds on the wider beneﬁts of rare
disease research, the potential impact of studying less common carti-
lage syndromes on osteoarthritis (OA) has been relatively neglected.
However, recent investigations from several laboratories have high-
lighted the more general lessons that can be learnt from research on
diseases such as chondrodysplasias, familial chondrocalcinosis, Kashin-
Beck Disease (KBD) and the osteoarthropathy of alkaptonuria (AKU).
Research on the rare mutations responsible for chondrodysplasias has
identiﬁed genes such as GDF5, which plays a key role in skeletal
development. Polymorphisms in this same gene provide one of the best
characterised genetic associations with OA susceptibility. Mutation of
the ANKH gene in chondrocalcinosis has highlighted the role that this
gene plays in the physiological and pathological mineralisation of car-
tilage. The expression of ANKH, which codes for a pyrophosphate
transporter is known to be dysregulated in OA. Research on KBD has
identiﬁed aberrations in gene expression and cell signalling some of
which are also observed in OA.
AKU is a single gene defect in tyrosine metabolism that leads to an early
onset, aggressive joint degeneration. Although joint destruction in AKU
is associated with the deposition of pigmented polymers in cartilage,
termed ochronosis, there are several parallels with the pathophysiology
of OA. Studies on tissue samples from patients with AKU, and from a
mouse model of the disease, have revealed previously unrecognised
microanatomical, cellular and biochemical changes in joints which have
been subsequently also detected in human OA. These include early
changes in the integrity of collagen ﬁbrils, the role of calciﬁed cartilage
in the initiation of OA, thinning and cracking of the subchondral plate
and aberrant non-Frostian bone remodelling with the formation of
novel microanatomical structures described as trabecular excrescences.
All of these features are abundant and easily recognisable in the severe
phenotype of AKU but require more careful observation in OA because
they occur at a lower frequency.
In conclusion, there is overwhelming evidence that studying rare car-
tilage syndromes with extreme phenotypes can help elucidate the
pathophysiological mechanisms involved in the initiation and pro-
gression of joint destruction. Further support for rare disease research1063-4584/$ – see front matter“apart from the beaten paths” could make a signiﬁcant contribution to
the development of effective therapies for OA and the identiﬁcation of
new biomarkers.
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MICRO-RNA AND CHONDROCYTE FUNCTION
M. Sato. Tokai Univ. Sch. of Med., Isehara, Japan
MicroRNAs (miRNAs) are single-stranded noncoding RNAs ofw22 base
pairs that regulate gene expression by repressing translation. In 1993,
the ﬁrst miRNA, lin-4, was discovered in nematodes, and subsequent
studies have shown that miRNAs regulate w30% of all human genes.
miRNA is transcribed initially from miRNA genes into a long primary
transcript (pri-miRNA), which is then cleaved by Drosha to produce
precursor miRNA (pre-miRNA). The pre-miRNA is then transported to
the cytoplasm using exportin-5, and there it is cleaved by Dicer to yield
miRNA. The miRNA then combines with an argonaute protein to form
RISC, which sequence-speciﬁcally recognizes and represses the trans-
lation of target RNAs. Abnormalities in cartilage development have been
observed in Dicer gene dysfunction models, and miRNA is known to
play a key role in cartilage differentiation. miRNA plays a key role in
differentiation and growth in organs and tissues, andmiRNAs expressed
speciﬁcally in cartilage have been reported. To date, miR-21, miR-22,
miR-27a, miR-140, miR-146, and so on have been reported as miRNAs
that are associated with cartilage metabolism. Many studies have
reported the use of a microarray analysis for isolating miRNAs that are
expressed in a tissue-speciﬁc manner. For example, Miyaki et al. per-
formed microarray analysis of mesenchymal stem cells and articular
chondrocytes, and they observed a high expression of miR-140 in
chondrocytes. They also observed that the expression of miR-140
increased during chondrogenesis. In addition, they reported that miR-
140 expression was lower in the osteoarthritis (OA) group than in the
normal group. Iliopoulos et al. performed microarray analysis using
normal chondrocytes and chondrocytes isolated from OA. They repor-
ted an increased expression of miR-22 and a decreased expression of
miR-140 in the OA group. They also reported that the expressions of IL-
1beta and MMP13 were increased, whereas the expression of aggrecan
was decreased in the group that showed increased miR-22 expression.
On the other hand, using microarray analysis, we focused on three types
of miRNAs, i.e., miR-199a-3p, miR-193b, and miR-320c, and their
expressions were observed to vary with age. We harvested cartilage
tissue from patients with polydactylism, anterior cruciate ligament
injury, and OA undergoing total knee arthroplasty, and we used
microarrays to identify miRNAs whose expression is upregulated or
downregulated with age. The results were assessed by real-time PCR
and MTT assay in a mimic group, in which synthetic double-stranded
RNA from the isolated miRNAwas transfected to upregulate expression,
and in an inhibitor group, inwhich the miRNAwas bound speciﬁcally to
downregulate expression. The expression of two miRNAs (miR-199a-3p
and miR-193b) was upregulated with age, and that of one miRNA (miR-
320c) was downregulated with age. A real-time PCR assay showed that
type 2 collagen, aggrecan, and SOX9 expression were downregulated in
the miR-199a-3p mimic group but were upregulated in the inhibitor
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ADAMTS5 expressionwas downregulated in the miR-320c mimic group
and upregulated in the inhibitor group. Cell proliferative activity was
upregulated signiﬁcantly in the miR-193b inhibitor group compared
with the control group. We believe that miR-199a-3p and miR-193b are
involved in the senescence of chondrocytes and that miR-320c is
involved in the juvenile properties of chondrocytes.
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OA PHENOTYPE AND THERAPY
P. Conaghan. Univ. of Leeds, Leeds, United Kingdom
Purpose: There is a massive unmet need for effective osteoarthritis (OA)
therapies, both symptom and structure modifying. The application of
modern imaging modalities such as magnetic resonance imaging (MRI)
and ultrasound has led to ground-breaking advances in understanding of
the OA phenotype. As yet the revolution in disease knowledge has not
been mirrored by improved therapeutics, but increasingly the OA liter-
ature demonstrates a shift toward personalised, pathology-targeted
interventions. In typical symptomatic OA, modern imaging has demon-
strated abundant pathology; inﬂammation (visualised as synovitis) and
subchondral bone pathology are much more common than previously
considered. Synovitis has been reported extremely commonly, with
detection reﬂecting the sensitivity of the imaging tool employed.
Although generally less in volume and vascularity than in rheumatoid
arthritis (RA), the inﬂammatory cells and mediators present are very
similar. This imaging-detected synovitishas been associatedwith thepain
of OA, and also identiﬁed as an independent predictor of progression to
joint replacement. Of our current symptomatic pharmacological agents,
the 2with consistentlymodest analgesic effect sizes areNSAIDs and intra-
articular corticosteroids - both of which have signiﬁcant anti-inﬂamma-
tory actions. Oral corticosteroid at low dose failed to beneﬁt hand OA in a
recent RCT; however a larger dose did have analgesic effects in a knee OA
study. Disease modifying anti-rheumatic drugs are used in rheumatoid
arthritis (RA) for their effect on theprimary disease inﬂammatoryprocess,
resulting in reduction in symptoms and consequent retardation of
structural joint damage. Such DMARDs were historically not considered
for OA as it was not primarily an inﬂammatory arthritis. However a small,
open label study of methotrexate demonstrated analgesic efﬁcacy
equivalent to that of an NSAID. Trials targeting IL-1 with a number of
monoclonal antibody inhibitors have been disappointing in terms of
symptom control. Several recent studies have investigated the effects of
anti-TNF therapies in OA, with variable results. Studies of erosive hand OA
have resulted in reduced swollen joint counts and reduced structural
deterioration in joints with baseline clinical synovitis, but generally there
have been no sustained analgesic beneﬁts, though often anti-TNF therapy
was given for short duration. Fewer studies have been conducted in knee
OA, although a small number open-label study suggested good analgesic
response. MRI-identiﬁed bone marrow lesions (BMLs) have provided
insights intosubchondralbonearchitectural failure andare related toboth
pain and ipsilateral compartment progression of knee OA. A number of
pharmacological therapies with potential to positively affect trabecular
structure (as well as direct potential beneﬁts for cartilage) have recently
demonstrated beneﬁts in large OA trials, including calcitonin, strontium
andzoledronic acid; the latter2 therapieshave inparticulardemonstrated
reductions in BMLs and associated reductions in knee pain. These exciting
though relatively early attempts at phenotype-targeted therapies provide
the basis for strong growth in this ﬁeld, and improved molecular tissue
phenotyping should further enhance the range of targets and potential
therapeutics.
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NOVEL APPROACHES TO JOINT REPAIR
F. Guilak. Duke Univ. Med. Ctr., Durham, NC, United States
Purpose: The repair of articular cartilage following joint injury or
degeneration remains an important challenge for the ﬁeld of tissue
engineering. While a number of techniques have been developed over
the years for the treatment of small cartilage defects, there have been
few attempts at tissue-engineered therapies for end-stage osteo-
arthritis. Some of themajor considerations for this approach include the
identiﬁcation and characterization of an abundant and accessible cell
source as well as the design of biologically and mechanically functional
scaffolds that can withstand joint loading.Methods: Here we describe the engineering of large, anatomically-
shaped cartilage constructs using different stem cell sources (adipose
stem cells, mesenchymal stem cells, or induced pluripotent stem cells),
combined with mechanically functional cell-instructive scaffolds.
Under appropriate culture conditions, these stem cells exhibit a chon-
drogenic phenotype and can synthesize cartilage-speciﬁc matrix pro-
teins that are assembled in a functional extracellular matrix. An
important consideration in the long-term success of such tissue
replacements is a more thorough investigation of the inﬂuence of bio-
mechanical factors, such as the design and characterization of the
mechanical properties of biomaterial scaffolds and the use of bio-
physical stimuli to control cell differentiation and metabolism.
Results: Using principles of “functional tissue engineering”, we have
developed novel biomimetic scaffolds, based on techniques for three-
dimensional weaving of biocompatible ﬁbers, which can conform to
contoured surfaces. Such moldable composite scaffolds can be engi-
neered with initial properties that reproduce the anisotropy, viscoe-
lasticity, and tension-compression nonlinearity of native articular
cartilage, providing the potential for complete resurfacing of the entire
joint surface. The ability to control stem cell fate in vivo may provide
more direct approaches for translation of these tissue-engineering
techniques by minimizing ex vivo manipulation of cells and repair tis-
sues. In this regard, these textile processing techniques allow site-
speciﬁc delivery of proteins or genes to facilitate the formation of
complex inhomogenous tissues from a single cell source. Furthermore,
this method can be adapted to confer tunable and inducible immuno-
modulatory properties to stem cells for controlled drug delivery to the
joint.
Conclusions: Recapitulating the biomechanical properties of the tissue,
in addition to providing developmental, biophysical, and immunomo-
dulatory cues to the stem cells, may provide new advances in the
engineering of functional tissue replacements as a therapy for end-
stage osteoarthritis.
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STUDIES OF POST-TRAUMATIC OSTEOARTHRITIS-IMPLICATIONS FOR
UNDERSTANDING OF THE ROLE OF MECHANICAL FORCES IN THE
ONSET AND PROGRESSION OF OSTEOARTHRITIS
J.A. Buckwalter, J.A. Martin. Univ. of Iowa, Iowa City, IA, United States
Purpose: Excessive joint loadings, either single (acute contact stress) or
repetitive (cumulative contact stress), cause progressive joint degen-
eration and subsequent development of the clinical syndrome of
osteoarthritis (OA). Joint injuries causing acute excessive contact stress
are common and often affect young adults: each year one in 12 people
between the ages of 18-44 seeks medical attention for treatment of
joint injury, and more than 12% of all lower limb OA is caused by joint
trauma. Despite advances in surgical treatment and rehabilitation of
injured joints, the risk of OA following joint fractures has not decreased
in the last 50 years. For these reasons there is a critical need to advance
understanding of how mechanical forces cause progressive loss of
articular cartilage and the syndrome of osteoarthritis.
Methods: We have conducted a series of in vitro, in vivo and clinical
studies with the intent of discovering howacute and cumulative contact
stress cause osteoarthritis.
Results: Cumulative excessive articular surface contact stress that leads
to OA results from joint dysplasia, incongruity and instability, but also
may cause OA in patients without known joint abnormalities. Advances
in understanding of the thresholds for mechanical damage to articular
cartilage, and of the biologic mediators that cause progressive loss of
articular cartilage due to excessive mechanical stress, will lead to better
treatments of joint injuries and improved strategies for restoring
damaged joint surfaces. Recent in vitro investigations show that reactive
oxygen species (ROS) released from mitochondria following excessive
articular cartilage loading can cause chondrocyte death and matrix
degradation and reduce the ability of chondrocytes to respond normally
to physiologic loading. Alarmins released from damaged chondrocytes
trigger an inﬂammatory response that can cause loss of cartilage. Pre-
venting the release of ROS or inhibiting their effects preserves chon-
drocytes and their matrix. Blocking the effects of Alarmins decreases
the inﬂammatory response. Fibronectin fragments released from
articular cartilage subjected to excessive loads also stimulate matrix
degradation; inhibition of the molecular pathways initiated by these
fragments prevents this effect. Distraction and motion of osteoarthritic
articular surfaces in humans can promote joint remodeling, decrease
